STML - Stemline Therapeutics, Inc.
| Previous Close | 9.97 |
| Open | 9.86 |
| Bid | 9.40 x 1000 |
| Ask | 11.00 x 800 |
| Day's Range | 9.76 - 10.42 |
| 52 Week Range | 9.65 - 20.55 |
| Volume | 379,818 |
| Avg. Volume | 276,598 |
| Market Cap | 300.85M |
| Beta (3Y Monthly) | 1.01 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.96 |
| Earnings Date | Mar 14, 2019 - Mar 18, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 28.50 |
SmarterAnalyst•9 days agoStemline Therapeutics (STML): Elzonris Approval Dawning on the Horizon, Says Analyst
Earlier this week, Stemline Therapeutics (STML) showcased clinical data of Elzonris (tagraxofusp) in blastic plasmacytoid dendritic cell neoplasm (BPDCN), chronic myelomonocytic leukemia (CMML) and myelofibrosis (MF) at the American Society of Hematology (ASH) 2018 meeting in San Diego, CA.
SmarterAnalyst•9 days ago3 Biotech Stocks That Could Explode Higher in 2019
Analysts think there are three biotech stocks, in particular, that look like good picks right now: Stemline Therapeutics (STML), Global Blood Therapeutics (GBT), and Sesen Bio (SESN). The application has received priority review from the FDA and has a PDUFA date scheduled for February 21, 2019, which is when regulators will decide the drug's commercial fate. ELZONRIS has also been granted Breakthrough Therapy Designation and Orphan Drug Designation by the FDA. "Given the strength of the pivotal study data combined with the significant unmet clinical need for BPDCN patients, we believe there is a strong likelihood of approval by the PDUFA date," Ladenburg analyst Matthew Kaplan opined. "We believe SL-401 could generate $130 million U.S. revenues in the BPDCN indication at peak.
- GlobeNewswire•10 days ago
Stemline Therapeutics Recaps Key Clinical Data Presentations from the American Society of Hematology (ASH) Annual Meeting
NEW YORK, Dec. 06, 2018 -- Stemline Therapeutics, Inc. (Nasdaq: STML), a biopharmaceutical company focused on the development and potential commercialization of novel oncology.
- GlobeNewswire•16 days ago
Stemline Therapeutics Highlights Four ELZONRIS Presentations, Including an Oral Presentation, at the Upcoming ASH Meeting
NEW YORK, Nov. 30, 2018 -- Stemline Therapeutics, Inc. (Nasdaq: STML), a biopharmaceutical company focused on the development and commercialization of novel oncology.
- GlobeNewswire•19 days ago
Report: Developing Opportunities within Koppers, Flowers Foods, Stemline Therapeutics, Aqua Metals, athenahealth, and Bojangles' — Future Expectations, Projections Moving into 2018
NEW YORK, Nov. 27, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- Simply Wall St.•24 days ago
What Kind Of Investor Owns Most Of Stemline Therapeutics Inc (NASDAQ:STML)?
Every investor in Stemline Therapeutics Inc (NASDAQ:STML) should be aware of the most powerful shareholder groups. Institutions often own shares in more established companies, while it’s not unusual to see Read More...
- GlobeNewswire•26 days ago
Stemline Therapeutics Announces that European Medicines Agency (EMA) Grants Accelerated Assessment for planned ELZONRIS Marketing Authorization Application (MAA)
Under European Union legislation, a medicinal product of major public health interest may be reviewed under an accelerated assessment procedure. Accelerated assessment can significantly reduce the timeframe for the EMA Committee for Medicinal Products for Human Use (CHMP) to review an MAA. In the U.S., ELZONRIS was granted breakthrough therapy designation for the treatment of patients with BPDCN.
- GlobeNewswire•last month
Stemline Therapeutics Announces Oral Presentation of SL-701 Phase 2 Data in Second-Line Glioblastoma at the 23rd Annual Meeting of the Society of Neuro-Oncology (SNO)
NEW YORK, Nov. 16, 2018 -- Stemline Therapeutics, Inc. (Nasdaq: STML), a biopharmaceutical company focused on the development and potential commercialization of novel oncology.
- Associated Press•last month
Stemline Therapeutics: 3Q Earnings Snapshot
The New York-based company said it had a loss of 73 cents per share. The results fell short of Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was ...
- GlobeNewswire•last month
Stemline Therapeutics Reports Third Quarter 2018 Financial Results
NEW YORK, Nov. 08, 2018 -- Stemline Therapeutics, Inc. (Nasdaq: STML), a biopharmaceutical company focused on the development and potential commercialization of novel oncology.
- GlobeNewswire•last month
Stemline Therapeutics Announces Four ELZONRIS Presentations, Including an Oral Presentation, at Upcoming ASH Meeting
NEW YORK, Nov. 02, 2018 -- Stemline Therapeutics, Inc. (Nasdaq: STML), a biopharmaceutical company focused on the development and commercialization of novel oncology.
- GlobeNewswire•2 months ago
Stemline Therapeutics Announces SL-701 and SL-801 Clinical Data to be Featured, Including an Oral Presentation, at Upcoming ESMO 2018 Congress
NEW YORK, Oct. 16, 2018 -- Stemline Therapeutics, Inc. (Nasdaq: STML), a clinical-stage biopharmaceutical company developing novel oncology therapeutics, announced today that.
- GlobeNewswire•2 months ago
Consolidated Research: 2018 Summary Expectations for Casella Waste, ServiceNow, MKS Instruments, FirstEnergy, Stemline Therapeutics, and CMS Energy — Fundamental Analysis, Key Performance Indications
NEW YORK, Oct. 11, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- Business Wire•2 months ago
Newman Ferrara LLP Announces Corporate Governance Investigation of Stemline Therapeutics Inc. - STML
Newman Ferrara LLP announced today that the firm is conducting an investigation on behalf of shareholders of Stemline Therapeutics Inc. (“Stemline” or the “Company”) (STML) into potential breaches of fiduciary duty by the Company’s Board of Directors (the “Board”). Stemline, headquartered in New York, NY, is a clinical-stage biopharmaceutical company focused on the development and commercialization of oncology therapies. Newman Ferrara’s investigation focuses on decisions made by the Board, without shareholder approval, the result of which significantly diminish shareholder value and do not benefit the Company.
- GlobeNewswire•3 months ago
Stemline Therapeutics to Present at Upcoming Investor Conferences
NEW YORK, Sept. 28, 2018-- Stemline Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel oncology therapeutics, announced today that Ivan Bergstein, M.D., Stemline’ s CEO, is ...
- Simply Wall St.•3 months ago
When Will Stemline Therapeutics Inc (NASDAQ:STML) Turn A Profit?
Stemline Therapeutics Inc’s (NASDAQ:STML): Stemline Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of proprietary oncology therapeutics in the United States and internationally.Read More...
- Benzinga•4 months ago
Benzinga Pro's 5 Stocks To Watch Today
Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! TAL Education Group (ADR) (NYSE: TAL ) stock was trading ...
- Associated Press•4 months ago
Stemline Therapeutics: 2Q Earnings Snapshot
The New York-based company said it had a loss of 66 cents per share. The results did not meet Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for ...
- ACCESSWIRE•6 months ago
Biotechnology Firm PPCB, Shows Great Potential
Propanc BioPharma, Inc ( PPCB ) Market Cap: 2.4 M, current share price: $0.07 HENDERSON, NV / ACCESSWIRE / June 19, 2018 / Propanc Biopharma Inc. , a clinical stage biopharmaceutical company focusing on ...
